Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

FGFR tyrosine kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FGFR (34) FLT3 (4) Syk (1) Apoptosis (3) Autophagy (2) c-Fms (2) c-Kit (12) Drug Metabolite (2) EGFR (3) Insulin Receptor (1) Isotope-Labeled Compounds (1) PDGFR (23) RET (7) Src (5) VEGFR (24)
By Research Areas:	Cancer (35) Cardiovascular Disease (1) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Isotope-Labeled Compounds

Targets Recommended: FGFR Btk Syk DYRK Pyk2 BRK FAK FLT3 Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101296

PD-166866

5+ Cited Publications

FGFR Autophagy Cancer

PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC₅₀ of 52.4 nM.

PD-166866 5+ Cited Publications	FGFR Autophagy	Cancer
PD166866 is a selective *FGFR1* tyrosine kinase inhibitor with an IC₅₀ of 52.4 nM.

HY-112412

PDGFR Tyrosine Kinase Inhibitor III PDGF Receptor tyrosine Kinase Inhibitor III	PDGFR	Neurological Disease
PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .

HY-147619

FGFR-IN-4	FGFR	Cancer
FGFR-IN-4 is a potent inhibitor of *FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine* kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2022033532A1, compound 20) . FGFR-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147620

FGFR-IN-5	FGFR	Cancer
FGFR-IN-5 is a potent inhibitor of *FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine* kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2022042612A1, compound 3) . FGFR-IN-5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-156632

Resigratinib

KIN-3248
FGFR Cancer

Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor, with antineoplastic effect .

Resigratinib KIN-3248	FGFR	Cancer
Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor, with antineoplastic effect .

HY-100315

Tyrosine kinase-IN-1	VEGFR PDGFR FGFR	Cardiovascular Disease
Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 4, 20, 4, 2 nM for KDR, Flt-1, *FGFR1* and PDGFRα, respectively.

HY-101466A

E7090 succinate	FGFR	Cancer
E7090 succinate is an orally available, selective and potent inhibitor of **FGFR1, FGFR2 and FGFR3** tyrosine kinase activities, with IC₅₀ values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively .

HY-148779

FGFR3-IN-5	FGFR	Cancer
FGFR3-IN-5 is a potent and selective FGFR3 inhibitor with IC₅₀ values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1, respectively. FGFR3-IN-5 can be used in research of cancer .

HY-10981

Lenvatinib Maximum Cited Publications 42 Publications Verification E7080	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-10981A

Lenvatinib mesylate Maximum Cited Publications 42 Publications Verification E7080 mesylate	VEGFR FGFR PDGFR RET c-Kit	Cancer
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-149486

FGFR1 inhibitor 7	FGFR	Cancer
FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC₅₀ value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC₅₀ of 2.1 μM .

HY-10407

SU 5402 5+ Cited Publications	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively.

HY-19981A

Derazantinib Racemate ARQ-087 Racemate	FGFR	Cancer
Derazantinib Racemate (ARQ-087 Racemate) is the racemate of Derazantinib. Derazantinib is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against *FGFR1-3* chondrocytes with IC₅₀s of 4.5, 1.8, and 4.5 nM, respectively.

HY-10185

TG 100572 Hydrochloride 2 Publications Verification	Src VEGFR FGFR PDGFR	Inflammation/Immunology
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10184

TG 100572	Src VEGFR PDGFR FGFR	Cancer
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10981S1

Lenvatinib-d5 E7080-d₅	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-10981S

Lenvatinib-d4 E7080-d₄	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-133980

O-Demethyl Lenvatinib	Drug Metabolite	Cancer
O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .

HY-133980A

O-Demethyl Lenvatinib hydrochloride	Drug Metabolite	Cancer
O-Demethyl Lenvatinib hydrochloride is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. Lenvatinib shows potent antitumor activities .

HY-10981AR

Lenvatinib mesylate (Standard)	VEGFR FGFR PDGFR RET c-Kit	Cancer
Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-10981R

Lenvatinib (Standard)	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-12297

Sulfatinib 2 Publications Verification Surufatinib; HMPL-012	FGFR VEGFR	Cancer
Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, *FGFR1* and CSF1R with IC₅₀s of in a range of 1 to 24 nM.

HY-156618

Irpagratinib ABSK011	FGFR	Cancer
Irpagratinib (ABSK011) is an orally active inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinase, targeting to *FGFR4* (IC50<10 nM). Irpagratinib inhibits the auto-phosphorylation of FGFR4 and blocks signal transduction from FGFR4 to downstream pathway activation. Irpagratinib exhibits high exposure in PK study in mouse, rat and dog, and also shows antineoplastic/anti-tumor activity in subcutaneous xenograft tumor models .

HY-50905S

Dovitinib-d8	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-112452

SU11652	VEGFR FGFR PDGFR c-Kit Apoptosis	Cancer
SU11652 is a potent *receptor tyrosine* kinase (RTK)** inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, *FGFR, PDGFR, and Kit*. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research .

HY-10207

Dovitinib lactate 5+ Cited Publications CHIR-258 lactate; TKI-258 lactate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, *FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively .

HY-B0062

Dovitinib lactate hydrate TKI258 lactate hydrate; CHIR-258 lactate hydrate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, *FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively .

HY-112345

PD-089828	FGFR PDGFR EGFR Src	Cancer
PD-089828 is an ATP competitive inhibitor of *FGFR-1, PDGFR-β* and EGFR (IC₅₀s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC₅₀=0.18 µM). PD-089828 also inhibits MAPK with an IC₅₀ of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity .

HY-10517

Orantinib 3 Publications Verification SU6668; TSU-68	PDGFR FGFR VEGFR Apoptosis	Cancer
Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and *FGFR1*, respectively.

HY-10981S2

Lenvatinib-15N,d4 E7080-¹⁵N,d₄	VEGFR c-Kit FGFR RET PDGFR Isotope-Labeled Compounds	Cancer
Lenvatinib- ¹⁵N,d₄ is ¹⁵N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-50905

Dovitinib 5+ Cited Publications CHIR-258; TKI258	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib (CHIR-258) is an orally active, potent *multi-targeted tyrosine* kinase (RTK) inhibitor with IC₅₀s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ**, respectively. Dovitinib has potent antitumor activity .

HY-10186

TG 100801 1 Publications Verification	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10187

TG 100801 Hydrochloride	VEGFR FGFR PDGFR Src	Cancer
TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-13896

PD168393 2 Publications Verification	EGFR Autophagy Apoptosis	Cancer
PD168393 is a potent, selective and cell-permeable inhibitor of EGFR tyrosine kinase and ErbB2. PD168393 irreversiblely inactivates EGF receptor ( IC₅₀=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC .

HY-16135A

CEP-11981 tosylate ESK981 tosylate; BOL 303213X tosylate	VEGFR FGFR	Others
CEP-11981 (tosylate) (ESK981 (tosylate), BOL 303213X (tosylate)) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and *FGFR1*, and has potential anti-tumor and anti-angiogenic effects .

HY-16135

CEP-11981 ESK981; BOL 303213X	VEGFR FGFR	Cancer
CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and *FGFR1*, and has potential anti-tumor and anti-angiogenic effects .

HY-12297R

Sulfatinib (Standard)	FGFR VEGFR	Cancer
Sulfatinib (Standard) is the analytical standard of Sulfatinib. This product is intended for research and analytical applications. Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, *FGFR1* and CSF1R with IC₅₀s of in a range of 1 to 24 nM.

HY-118203

SU4984	FGFR PDGFR Insulin Receptor	Cancer
SU4984 is a protein tyrosine kinase inhibitor, with an IC₅₀ of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer .

HY-10407G

SU 5402	VEGFR EGFR PDGFR	Cancer
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively .

HY-109082

Cevidoplenib SKI-O-703	Syk	Inflammation/Immunology
Cevidoplenib (SKI-O-703) is an orally available inhibitor of *spleen tyrosine* kinase (Syk)*, with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases* with IC₅₀s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively .

Protein Tyrosine Kinase Compound Library	1,064 compounds
Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers. MCE designs a unique collection of 1,064 compounds that act as a useful tool for PTKs-related drug screening and disease research.

SU 5402 (GMP)	Fluorescent Dye
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively .

SU 5402 (GMP)	Biochemical Assay Reagents
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: